QDEL - Quidel Corporation
56.78 0.00 (0.00%)
After hours: 5:53PM EDT
| Previous Close | 56.87 |
| Open | 56.86 |
| Bid | 52.65 x 800 |
| Ask | 56.82 x 800 |
| Day's Range | 56.63 - 57.15 |
| 52 Week Range | 44.27 - 77.63 |
| Volume | 143,242 |
| Avg. Volume | 184,054 |
| Market Cap | 2.261B |
| Beta (3Y Monthly) | 1.62 |
| PE Ratio (TTM) | 35.40 |
| EPS (TTM) | 1.60 |
| Earnings Date | Aug 5, 2019 - Aug 9, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 71.40 |
- Simply Wall St.•2 days ago
Brief Commentary On Quidel Corporation's (NASDAQ:QDEL) Fundamentals
As an investor, I look for investments which does not compromise one fundamental factor for another. By this I mean, I...
- Investor's Business Daily•7 days ago
Are These Medical Stocks Cruising Toward Big Gains? Here's A Bullish Sign
Medical technology companies are rising bullishly in 2019. The best-performing medical stocks tend to have high Composite Ratings, reflecting strong growth metrics vs. all other stocks.
- Business Wire•28 days ago
Quidel Receives 510(k) Clearance for Quidel Triage® TOX Drug Screen, 94600 Toxicology Test for Use With Quidel’s Triage® MeterPro Instrumented System
Quidel Corporation (QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has received 510(k) clearance from the Unites States Food and Drug Administration (FDA) to market the Quidel Triage® TOX Drug Screen, 94600, a fluorescence immunoassay for the qualitative determination of the presence of drug and/or metabolites in human urine of up to 9 drug assays. The test is to be used with Quidel’s Triage® MeterPro instrumented system.
- Zacks•last month
Medical Products Industry Outlook: Growth Prospects Radiant
Medical Products Industry Outlook: Growth Prospects Radiant
- Zacks•last month
QDEL vs. BAX: Which Stock Is the Better Value Option?
QDEL vs. BAX: Which Stock Is the Better Value Option?
- Zacks•last month
Masimo's O3 Oximetry Gets FDA Nod, Boosts Patient Monitoring
Masimo (MASI) gets FDA nod for its O3 Regional Oximetry that will help in delivering accurate measurement with respect to neonatal patients.
- Insider Monkey•last month
Is Quidel Corporation (QDEL) A Good Stock To Buy?
As we already know from media reports and hedge fund investor letters, many hedge funds lost money in fourth quarter, blaming macroeconomic conditions and unpredictable events that hit several sectors, with technology among them. Nevertheless, most investors decided to stick to their bullish theses and recouped their losses by the end of the first quarter. […]
- Zacks•last month
Zacks.com featured highlights include: lululemon, Quidel, China Yuchai and Logitech
Zacks.com featured highlights include: lululemon, Quidel, China Yuchai and Logitech
- Zacks•last month
Ecolab Unveils Innovative Tested Tool to Improve Food Safety
Ecolab's (ECL) innovative tested tool aims to improve food safety and ensure customer safety.
- Zacks•last month
Here's Why You Should Invest in Integer Holdings (ITGR) Stock
Integer Holdings (ITGR) continues to benefit from portfolio management, strong foothold in the broader MedTech space and rising Non-Medical sales.
- Zacks•last month
Here's Why You Should Retain HMS Holdings (HMSY) Stock
HMS Holdings (HMSY) is gaining traction from the growing PI and TPM analytical services. However, stiff competition remains a concern.
- Zacks•last month
4 Top Efficient Stocks to Boost Your Portfolio
A company with a favorable efficiency level is expected to provide stellar returns as it is believed to be positively correlated with price performance.
- Simply Wall St.•last month
Should You Be Adding Quidel (NASDAQ:QDEL) To Your Watchlist Today?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
- Zacks•last month
Here's Why You Should Retain NextGen Healthcare (NXGN) Stock
NextGen Healthcare (NXGN) is gaining traction from the U.S. RCM market and the growing EHR market. However, margin pressure remains a concern.
- Zacks•last month
Here's Why You Should Invest in DexCom (DXCM) Stock Now
DexCom (DXCM) is gaining traction from lucrative glucose monitoring market, solid international market presence and strong product portfolio.
- Business Wire•last month
Quidel Announces Private Exchange Transactions
Quidel Corporation (QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it has entered into separate, privately negotiated exchange agreements with certain holders of its 3.25% Convertible Senior Notes due 2020 (the “2020 Notes”). Pursuant to these exchange agreements Quidel will exchange approximately $45.372 million in aggregate principal amount of the 2020 Notes for (i) approximately 1,273,601 shares of the company’s common stock plus (ii) an additional number of newly issued shares of the company’s common stock to be determined based on the volume weighted average price of the company’s common stock over the three consecutive trading days commencing on June 5, 2019.
- Zacks•last month
Here's Why You Should Hold on to Medidata (MDSO) Stock Now
Medidata Solutions (MDSO) continues to benefit from solid R&D focus, Rave Genomics platform and cloud-based services. However, stiff competition remains a concern.
- Zacks•2 months ago
Here's Why You Should Bet on Merit Medical (MMSI) Stock Now
Merit Medical (MMSI) continues to benefit from solid product pipeline, HeRO product line and persistent focus on R&D.
- Zacks•2 months ago
Here's Why You Should Consider Betting On CONMED Stock Now
CONMED (CNMD) continues to benefit from robust international sales, broad product portfolio and continued focus on R&D.
- Simply Wall St.•2 months ago
Here's What Quidel Corporation's (NASDAQ:QDEL) P/E Ratio Is Telling Us
Today, we'll introduce the concept of the P/E ratio for those who are learning about investing. To keep it practical...
- Zacks•2 months ago
ABIOMED Gets FDA Confirmation of the Safety of Impella RP
ABIOMED (ABMD) receives the FDA confirmation of the safety and effectiveness of the company's Impella RP heart pump.
- Business Wire•2 months ago
Quidel to Present at William Blair 39th Annual Growth Stock Conference
Quidel Corporation (QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at the William Blair 39th Annual Growth Stock Conference at the Loews Chicago hotel in Chicago, Illinois on Thursday, June 6, 2019. Randy Steward, chief financial officer, will present on Thursday, June 6, 2019 at 1:20 p.m. Central Time (11:20 a.m. Pacific Time) with a question-and-answer session scheduled immediately following the presentation. Participants should allow approximately five to ten minutes prior to the presentation's start time to visit the site and download any streaming media software needed to listen to the Internet webcast.
- Zacks•2 months ago
Masimo Gets FDA Nod for Radius PPG, Boosts Patient Monitoring
Masimo (MASI) receives FDA 510 (k) clearance for Radius PPG, which is set to become an important breakthrough in patient monitoring.
- Zacks•2 months ago
Here's Why You Should Retain Cooper Companies (COO) Stock
Cooper Companies (COO) is gaining traction from expansion in international markets, robust product portfolio across segments and prudent acquisitions. However, forex volatility remains a concern.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of QDEL earnings conference call or presentation 8-May-19 9:00pm GMT
Q1 2019 Quidel Corp Earnings Call
